Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

205.78 -1.54 (-0.74%)

Official Closing Price Updated: 7:00 PM EST, Dec 23, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

99 100 Next >

MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? ↗

January 19, 2025

These 11 large-cap stocks saw significant growth last week, with notable news from companies such as Johnson & Johnson, MicroStrategy, and United Rentals.

Via Benzinga

MarketBeat Week in Review – 01/13 - 01/17

January 18, 2025

The sell-off in stocks reversed abruptly this week on better-than-expected inflation readings; investors will want to see strong earnings to support the rally

Via MarketBeat

Topics Economy Energy

3 Super-Safe Dividend Stocks to Buy for 2025 and Beyond ↗

January 18, 2025

Via The Motley Fool

Wall Street's Greatest Dividend Stock -- a Small-Cap Company 99% of Investors Have Never Heard of -- Is the Cheapest It's Been in Over a Decade ↗

January 18, 2025

This magnificent company has been paying a continuous dividend to its shareholders since 1816.

Via The Motley Fool

Looking Into Johnson & Johnson's Recent Short Interest ↗

January 14, 2025

Via Benzinga

2 Beaten-Down Dividend Stocks to Buy in 2025 ↗

January 13, 2025

Via The Motley Fool

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt ↗

January 17, 2025

Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.

Via Benzinga

Topics Government

Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review ↗

January 17, 2025

Many stocks flashed buy signals as the major indexes rose to or above key levels.

Via Investor's Business Daily

Topics Economy

Is Johnson & Johnson Stock Set to Reward Long-Term Holders?

January 17, 2025

JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractive

Via MarketBeat

Smart Money Is Betting Big In JNJ Options ↗

January 02, 2025

Via Benzinga

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever ↗

January 17, 2025

These companies lead their respective markets, making them must-haves for buy-and-hold dividend investors.

Via The Motley Fool

10 One Decision Stocks To Buy Now ↗

January 15, 2025

The following 10 one decision stocks have increased their dividends for over 25 years, making them Dividend Aristocrats.

Via Talk Markets

Topics Stocks / Equities

Got $200? 2 Dividend Stocks to Buy and Hold Forever ↗

January 15, 2025

These companies headline a $1.4 trillion industry, have staying power, and will pay you well to hold their stock.

Via The Motley Fool

What Lies Ahead In 2025? Slower Growth, More Volatility ↗

January 14, 2025

As we move through 2025, the global economy and financial markets are facing a critical juncture.

Via Talk Markets

Topics Economy Stocks / Equities

Clinical Research Firm ICON Faces Headwinds From Top Customers And Biotech Recovery Uncertainty ↗

January 14, 2025

ICON forecasts 2025 revenue at $8.05 billion–$8.65 billion and adjusted EPS of $13.00–$15.00, citing biopharma spending cuts and biotech recovery delays.

Via Benzinga

Intra-Cellular Therapies Stock Is Surging Monday: What's Going On? ↗

January 13, 2025

Shares of Intra-Cellular Therapies Inc. (NASDAQ: ITCI) are trading higher Monday after Johnson & Johnson agreed to acquire the company.

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Paycor HCM, Inc. (Nasdaq - PYCR), Accolade, Inc. (Nasdaq - ACCD)

January 13, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal ↗

January 13, 2025

Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies boosts its CNS portfolio with Caplyta and a promising clinical-stage pipeline.

Via Benzinga

Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal ↗

January 13, 2025

The deal values the smaller biotech company at a 39% premium to last week's closing price.

Via Investor's Business Daily

Intra-Cellular Therapies Stock Shines Amid Market Slump On J&J’s $14.6B Buyout Deal: Retail Brims With Optimism ↗

January 13, 2025

ITCI's flagship product, Caplyta, is a once-daily oral therapy approved for treating schizophrenia and depressive episodes linked to bipolar disorders, which reportedly raked in sales of $464 million...

Via Stocktwits

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

January 13, 2025

From Johnson & Johnson

Via Business Wire

A Look At Dividend Kings ↗

January 12, 2025

In this video, we dive deep into 'Dividend Kings.' These are elite companies that have consistently increased their dividends for 50+ years.

Via Talk Markets

Topics ETFs Stocks / Equities

Stock Market Tumbles As Yields Spike; Nvidia, Tesla, Delta, Meta, Jobs Report In Focus: Weekly Review ↗

January 10, 2025

The S&P 500 and Nasdaq are below their 50-day lines.

Via Investor's Business Daily

Topics Stocks

4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025 ↗

January 10, 2025

These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal portfolio anchor stocks for a long-term investor.

Via The Motley Fool

2 Dow Stocks to Buy Hand Over Fist in 2025 and 1 to Avoid ↗

January 10, 2025

Among the Dow Jones Industrial Average's 30 components, there are two historically cheap brand-name companies, as well as a new member that's priced for perfection in an imperfect industry.

Via The Motley Fool

Topics Stocks

Johnson & Johnson Pauses US Varipulse Procedures Amid Safety Review, Investigates Brain-Related Events ↗

January 09, 2025

Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA therapy and 3D mapping for AFib treatment.

Via Benzinga

J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key Product ↗

January 08, 2025

The company paused sales of a key product, a rival to Boston Scientific and Medtronic, due to safety concerns.

Via Investor's Business Daily

8 Health Care Stocks Whale Activity In Today's Session ↗

January 08, 2025

Via Benzinga

Where to Invest $100,000 in 2025 ↗

January 08, 2025

Via The Motley Fool

Stock Of The Day: Will Johnson & Johnson Take The Market Lower? ↗

January 06, 2025

Shares of Johnson & Johnson are flat in Monday's trading. But they continue to test support. If this support breaks, it could be bearish for the entire market.

Via Benzinga

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Johnson & Johnson (NY:JNJ)

All News about Johnson & Johnson

Starting at $3.75/week.

Subscribe Today